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Abstract 
Background: To  assess patients’ and physicians’ 
perceptions regarding factors responsible for delay 
of Insulin initiation and compared.  
Methods: In this cross sectional study using mixed 
quantitative and qualitative approach, quantitative 
component included structured interviews of 400 
Type 2 Diabetic patients with failure to oral 
hypoglycemic agents (equally stratified based on 
gender and public or private health care settings) 
who had not initiated Insulin despite physicians 
advice. For qualitative aspect, 4 Focus group 
discussions with 29 consultant physicians of diabetic 
patients and four including 31 diabetic patients with 
delay were conducted.  The factors responsible for 
delay and mean duration of delays were assessed 
and also compared based on gender and health care 
type. 
Results: The mean duration of diabetes in 400 
patients was 12.91±3.78 years while the duration of 
delay in months was 23.08±14.62 months with highly 
statistically significant increase in female patients. 
Patients identified fear of injection or needle phobia 
as the commonest factor (24.62%), followed by fear of 
side effects of Insulin (18.87%). Consultant 
physicians in addition to same above factors also 
mentioned the role of quacks and fear of loss of 
patients by doctors as important factors. 
Conclusion: Factors identified by patients and 
physicians responsible for delay of initiation of 
insulin included perceptions of  fears, difficult and 
lifelong application, cost, storage issues, last resort 
of treatment, misdirection from quacks and patients 
reluctance tempting doctors to hold up insulin till 
inevitable. 
Key Words: Insulin,Diabetes Mellitus Type 2, 
Hypoglycemic agents 
Introduction 
Delay in initiation of Insulin in type 2 Diabetic 
patients, with secondary failure of oral hypoglycemic 
agents, is a serious issue and may lead to early 
development of diabetic complication. .1 The 
prevalence of diabetes in the world was 8.3% while in 
Pakistan it was 7.89% in 2011 .2  It had shown an 
increase in Pakistan since 2007 when the prevalence of 
diabetes in the urban versus the rural areas was 6.0% 
in men and 3.5% in women against 6.9% in men and 
2.5% in women, respectively.3  Globally the number of 
people with diabetes has risen from 108 million in 1980 
to 422 million in 2014 and the rise is more significant in 
middle and low income countries. Diabetes alone was 
directly responsible for an estimated 1.5 million deaths 
in 2012.. 4  World Health Organization projects that 
diabetes will be the 7th leading cause of death in 
2030.5 The  gravity of the situation is reflected by the 
projected number of people with diabetes to rise from 
171 million in 2000 to 366 million in 2030.6 Diabetes 
mellitus type 2 or Type 2 diabetes makes up about 90% 
of cases of diabetes (remaining contributed by diabetes 
mellitus type 1 and gestational diabetes) and is 
distinguished by insulin resistance, high blood sugar 
and relative lack of insulin7-10  
The complications of type 2 diabetes include heart 
disease, stroke, diabetic retinopathy which can result 
in blindness, kidney failure, and even amputations.7 
There is a need to timely prevent, diagnose and 
manage type 2 diabetes. Its recommended 
management include trial of diet and exercise but in 
case of failure to attain normal glycemic control within 
a three-month period with both, pharmacological 
intervention in the form of oral hypoglycemic agents is 
required.11-13 With progressive disease, in type 2 
diabetes patients diminished insulin secretion due to 
declining β-cell function eventually leads to 
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uncontrolled glycemic control even with oral agents 
and most patients need treatment with exogenous 
insulin at some point during their lifetimes.14-16 The 
effectiveness of early progression to insulin has not 
only  resulted in attainment of good glycemic control 
but also prevents complications. 17-19 
In spite of evidence of effectiveness, the common 
practice is that Diabetic patients are reluctant to 
initiate Insulin therapy. 20  It is a common practice to 
observe delay in initiation even in developed countries 
as study in UK showed that 25% of patients with 
Type 2 diabetes had insulin initiation delayed for at 
least 1.8 years, and 50% of patients delayed starting 
insulin for almost 5 years after failure of glycaemic 
control even in the presence of diabetes-related 
complications. 21. Various qualitative studies have 
identified common barriers directing the type 2 
diabetic patients to delay  initiation of Insulin were 
related to negative concerns and beliefs related to 
Insulin like as fear of Injection, needle phobia,  pain, 
inconvenience, embarrassment, lifestyle restriction, 
social stigma, and poor self-efficacy, prolonged 
treatment period, hypoglycemia, difficult technique.22-
30 Unfortunately the delay is not only attributed to 
patients alone, research has shown that even health 
care providers also have contributed to this delay in 
initiating Insulin in type 2 patients, in spite of clinical 
requisite, due to their attitude  and difficulty in 
explaining and  training patients regarding Insulin.31,32 
  
Patients and Methods  
 This cross sectional study, using mixed quantitative 
and qualitative approach was conducted in 
Rawalpindi from November 2014 to February 2016 . 
Study population comprised of type -2 diabetes 
mellitus patients , with ages above 40 years and who 
in spite of advice by the Medical consultant to initiate 
Insulin (due to secondary failure of hypoglycemic 
agents) had not initiated Insulin since advice. All the 
pregnant women or those diagnosed as cases of 
gestational diabetes and type-2 diabetic patients 
having any acute surgical problem, severe infections 
or any condition for which they were advised to 
initiate Insulin temporarily by the doctors i.e. other 
than, secondary failure of hypoglycemic drugs were 
excluded. Patients admitted or advised admissions in 
the indoor department of facilities were also not 
included. The patients were selected from Benazir 
Bhutto Hospital and from two private diabetic centers. 
The qualitative paradigm of the study embraced the 
assessment of the perspectives of health care 
providers(n=29). Medical consultants having at least 
10 years of clinical experience of diagnosing and 
managing  type 2 diabetes patients ) regarding the 
factors responsible for delay in initiation of insulin 
therapy by patients of type 2 diabetes with secondary 
failure to oral hypoglycemic agents both on part of 
patients and the health care providers and 
consequences of this delay. Four Focus Group 
Discussions (FDG’s) were conducted including 6-8 
medical consultants in each, two with public health 
care providers and two with those practicing in 
private setups. Since the qualitative method was also 
adopted to determine the perceptions of patients 
themselves regarding the reasons for delay, therefore 
four Focus Group Discussions were also conducted 
with 31 diabetic patients.The selection of the 
participants for FDG’s was made through purposeful 
homogenous sampling and snowball or chain 
sampling technique. The quantitative aspect of the 
study comprised of structured interviews of diabetic 
patients who delayed the initiation. Keeping the 
anticipated proportion of factors for delay as unknown 
(hence 50%), level of confidence 95% and absolute 
precision as 5%, the minimally required sample 
through WHO calculator was calculated to be 385, 
however 400 patients were included 200 from private 
sector and 200 from public sector, amongst each sector 
and patients were further stratified based on gender 
keeping half males and half females. The responses of 
interviews were then was entered and analyzed in 
Statistical Package of Social Sciences (SPSS). Pearson’s 
Chi square test was applied at 5% level of significance, 
to compare the factors based on gender and public or 
private sectors. Since the numerical variables like age 
of patients, duration of Diabetes and duration of 
delays were not normally distributed, therefore Mann-
Whitney U test was applied at 5% level of significance 
to compare their means ranks based on gender and 
public or private sectors.  
The mean age of the study participants in years, along 
with duration in years since diabetes was diagnosed 
(duration of Diabetes) and duration in months since 
when they were advised to switch to insulin from oral 
hypoglycemic agents by their doctors for first time 
(duration of delay)   The same variables were used to 
compute the mean ages of patients at which Insulin 
was advised for first time (present age minus duration 
of delay)  and  mean duration of  diabetes in years 
when insulin was advised (Duration of Diabetes minus 
duration of delay). 
Results 
 Statistically significant differences were observed 
amongst gender groups where females had higher 
mean values, however the variables were homogenous 
in public and private patients (Table 1). Majority of 
Journal of Rawalpindi Medical College (JRMC); 2016;20(4): 244-250 
 246 
patients (77.5%) confessed that they were shocked, 
surprised and afraid to hear about initiation of 
insulin(p-value 0.001). Only 35 patients (8.8%) stated 
that they agreed with the doctors decision of switching 
to insulin .Injection phobia was the commonest factor 
for delay in initiating insulin (Table 2). 
 When study participants were asked if they continued 
receiving treatment from the same doctors once 
he/she had advised them to initiate insulin treatment, 
(32.2%) told they stopped receiving treatment from 
that doctor. One hundred and sixty seven (41.8%) 
continued management of diabetes from same doctor 
on regular basis. 167 Patients, who continued regular 
management from same doctors, still did not initiate 
insulin but had insisted their doctor to either change 
oral hypoglycemic agents (53.29%) or continue with 
their same doses with assurance of strict diet control 
and exercise (46.70%). 233 patients who either 
discontinued consultation from same doctor, or 
became irregular in consultations had either initiated 
consultation from a new doctor (57.93 %), shifted to  
hikmat/herbal treatment (17.59%), homeopathic 
treatment(7.29%), spiritual healers or Aalim (5.57%), 
or discontinued any type of treatment and relied on 
exercise and diet control only (11.58%). 
 
Table 1. Descriptive statistics of durations 















60.72±6.69 62.13±6.6 59.31±6.44 ***0.00 61.2±7.36 60.1±5.93 0.22 

































Age (in years) at 


































* Standard Deviation ** Statistically Significant ***Highly Statistically Significant  
 
Table 2. Factors responsible for delay in initiation of insulin 
Factors responsible   All Males Female p-values Public Private p-values 
Fear of injection/needle phobia 24.62% 27.25% 22% 0.08 36.25% 13% **0.00 
Side effects like hypoglycemia weight gain, 
local swelling &  infection 
18.87% 21.75% 16% *0.03 18.75% 19% 0.92 
Difficulty in storage and transport 6% 3% 9% **0.00 8.5% 3.5% **0.00 
Social stigma 2.37% 1.75% 3% 0.24 2.5% 2.25% 0.81 
Last resort of treatment of Diabetes 2.12% 3.25K% 1% *0.02 3.25% 1% *0.02 
Painful 12.87% 7.5% 18.25% **0.00 9% 16.75% **0.00 
Difficulty in understanding the procedure  5.37% 6.5% 4.25% 0.15 4.25% 6.5% 0.15 
Difficult process of application and dosage 11.12% 13.5% 8.75% *0.03 5.5% 16.75% **0.00 
Expensive non affordability 9.62% 5% 10.5% **0.00 3.75% 11.75% **0.00 
No one to assist or facilitate injection 2.12% 3% 1.25% 0.08 2.25% 2% 0.80 
Does not control Diabetes effectively 5.5% 6.75% 4.25% 0.12 4.75% 6.25% 0.35 
No specific reason 1.25% 0.75% 1.75% 0.20 1.25% 1.25% 1.00 
*Statistically Significant  **Highly  Statistically Significant 
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Table 3. Findings of focus group discussions 
Perceptions of Participants of  FDG’s  
Reasons for delay in treatment initiation  
Fears:♣ Injection or needle phobias ♣Adverse effects like 
Hypoglycemia, weight gain, infections or allergic manifestations 
◄Patients absconding treatment from doctor if prescribed or 
insisted on Insulin initiation. 
Societal:♣ Stigma and embarrassment  ▄ Extra burden on 
caregivers  ▄ Resistance by spouse/family members ♣ Lack of 
facilitation and support by caregivers. 
Beliefs regarding insulin:♣ Last resort of treatment ♣ Lifelong once 
started/ no turning back after Insulin  ♣Anticipated ineffectiveness 
of Insulin. 
Concerns regarding application and storage: ♣Difficulty in learning 
and acquiring skills to apply Insulin injection and dose adjustment 
 ♣ Complexity of storage and transport ◄lack of Diabetic assistants 
and shortage of time to explain the patients in detail the procedure 
of application individually and to address their concerns ▄ 
Illiteracy    
Cost: ♣Expensive ♣lifelong expenditure ♣Non affordability ▄ 
Economic burden on care givers. 
Patients’ qualms:  ▄ Doctors’ personal gains and rewards from 
Pharmaceutical companies by prescribing Insulin ♣Doctor’s 
incompetency to attain glycemic control through oral agents. 
Patients’ unawareness:◄Regarding increased risks of Diabetic 
complications and serious consequences if not initiated Insulin 
◄Benefits of Insulin ♣Latest technological developments like pen 
Injectors.  
Lack of self reliance: ♣Patients lack of confidence and self reliance 
regarding compliance of Insulin treatment ▄ Anticipated 
incapability appropriate procedure of application of Injection and 
dose adjustment.     
Religious beliefs:◄Concerns regarding injecting medicines 
affecting religious rituals ◄Strong belief in Aalims and spiritual 
leaders. 
Consequences of delay 
♣Persistent Poor glycemic control  ♣ Deterioration of glycemic 
control ◄Early Development of Diabetic complications ▄ Allah’s 
will ◄Unnecessary and continuous exposure to overdosed Oral 
hypoglycemic agents leading to its adverse effects ▄ Nothing 
serious ♣Discontinuation of current Diabetic treatment in 
disappointment ◄Resort to spiritual leaders, hakims, homeopathic 
treatment and quakes. 
Recommendations to avoid delay 
◄Awareness campaign to educate Diabetic patients regarding 
benefits and necessity of Insulin through media ♣Training of 
appropriate procedure of application ◄Appointment of Diabetic 
nurses and Diabetic educator at health care facilities for detailed 
counseling of Diabetic patients ◄Strict policies against quakes 
claiming Insulin dangerous and attracting diabetic patients  with 
false slogans  ▄ Provision of domiciliary services to inject Insulin ▄ 
Formulation of Insulin tablets 
 ♣ Perceptions expressed by both Diabetic Patients & Consultant 
Physicians ; ◄ Opinions of consultant Physicians only 
   ▄ Perceptions of diabetic Patients Only 
 
Two hundred and thirty seven (59.25%)of total 
patients informed that their blood sugar levels had 
remained persistently uncontrolled since refusal to 
initiate insulin.In qualitative component  diabetic 
patients shared that needle phobia was a main reason 
for their delay in initiation of insulin treatment (Table 
3). Participants of focus group discussions, specifically 
the females, were also reluctant to use it in public to 
avoid social rejection, embarrassment and to be 
considered as if suffering from a serious ailment. Some 
of the participants had belief that Insulin is the last 
option and causes hypoglycemia and weight gain. All 
the participants of focus group discussions were 
concerned about Insulin’s storage and transportation 
issues. Many participants were not able to manage 
insulin treatment because  of the non – cooperative 
attitude of care givers or not to give an extra burden to 
their families .  
 Almost all physicians were in accord that patients 
were reluctant to initiate insulin the instant they are 
prescribed for the first time and it was exceedingly 
rare that any patient was agreeable and keen to initiate 
it on first advice. Many participant consultants shared 
that psychological factor are the main reasons behind 
delay in initiation of Insulin treatment. Elderly patients 
were more reluctant because they resist recent 
technological treatments as well as lack of facilitation 
by their care givers. Another concern expressed by 
doctors was that patients receiving Insulin if ever 
experienced any adverse effect of Insulin he/she 
would exaggerate it and publicized it in a way that 
other relatives requiring insulin develop fear and 
refuse it. Few physicians belonging to private health 
care agreed that due to anticipated reluctance by 
patient, doctors keep on pending its advice as last 
resort, so the delay is partly contributed by doctors 
too. 
Another issue highlighted in FDG’s was of Quacks 
who claim to be Dialectologists through media 
campaign, warning diabetic patients never to take 
Insulin and claiming permanent treatment of Diabetes 
through treatment of Pancreas. Majority of consultants 
expressed their concerns that all the patients refusing 
insulin wasted their precious time due to delay in 
initiation and when presented again after a long 
period most of them had developed irreversible 
precarious complications of diabetes.  
Discussion 
Apart from the serious challenge posed by type 2 
Diabetes Mellitus due to its rapid rise globally; the fact 
that its causation is based on intricacy of complex 
genetics and societal framework that determines 
behavior and environmental influences is also leading 
to serious concerns.33 Contrary to other chronic 
ailments, in which the aim of management is to 
achieve complete cure, diabetes is at variance where 
the target is to maintain normal glycemic control, 
prevention of complications and to strive for good 
quality of life of patients through strict diet control, 
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exercise and modification in life style. Lifetime 
pharmacological management is an ordeal for diabetic 
patients who are in continuous effort to remain 
compliant and to handle the oscillatory doses on 
regular basis. After prolonged pharmacological 
treatment with oral hypoglycemic agents spanning 
over years and their failure, the news of initiation of 
insulin might be onerous for patients where the timing 
of initiation is critical and well timed start can prevent 
complications.  
The mean duration of diabetes in our type 2 diabetic 
patients delaying initiation of Insulin was 12.91±3.78 
years, where in Japanese population it was estimated 
to be 10.31 years.31 The mean age of our patients 
requiring insulin initiation was 58.79±6.19 years where 
this mean age of females was higher than males with a 
highly statistically significant difference. The mean 
period of diabetes since its diagnosis till requirement 
of Insulin was observed to be 10.98±3.66 years, again 
with higher duration in female patients comparatively. 
This showed that not only females developed type 2 
diabetes in a slightly higher age compared to men; the 
need to initiate Insulin was also slightly delayed in 
them. The mean period of diabetes since its diagnosis 
till requirement of Insulin is consistent with Turner 
RC, who concluded that 9 years after diagnosis of 
diabetes, majority of patients would need the addition 
of insulin therapy to obtain an HbA1c level below 7%.34 
The mean duration of delay of Insulin since advised in 
our patients was 1.92±1.21 years compared to 1.8 years 
projected in UK population after failure to oral 
agents.21  
Majority of barriers or factor responsible for delay in 
initiation of Insulin from patient’s perspective 
identified in our study are in consistency with 
previously conducted studies in other parts of the 
world. 20-31,35   Like most of these our  study also 
identified fear of injection or needle phobia as the 
commonest one (24.62%), followed by fear of side 
effects like hypoglycemia weight gain (18.87%),pain 
(12.87%) difficult procedure of application and dosage 
(11.12%) and expensiveness (9.62%). Social Stigma was 
mentioned by only 2.37% of our 400 interviewees 
similarly though these issues were discussed in detail 
but emphasized by only few in Focus group 
discussions, an issue perceived much important in 
previous studies. 22, 24-26,35  Otherwise qualitative and 
quantitative paradigms of our study supported each 
other generally. As identified by many international 
studies, perception of self failure, self blame was not 
observed in our population.20,25,32,36,37 
The comparison of factors based on gender revealed, 
that higher number of male patients compared to 
females mentioned the factors regarding the side 
effects of the Insulin, difficult procedure of application 
and storage of Insulin injections and perceiving Insulin 
as last resort of treatment responsible, for delay in 
initiation. Surprisingly the fear of injection was 
specified more by males than females in addition to 
perceived ineffectiveness of Insulin and lack of 
facilitators for injections even though differences were 
not statistically significant.  However, females were 
more concerned with issues of pain associated with 
Insulin injection and expensive treatment, difference 
being highly statistically significant compared to 
males, they were higher in proportion mentioning 
social stigma associated with Insulin. The statistically 
significant contrast in public and private patient’s 
priority issues was regarding the fear of injection, 
difficulty of storage and last resort of treatment 
highlighted more by public health care patients where 
pain, expensiveness and difficult procedure of 
application were solemn apprehensions of private 
patients. 27,31,32,33,35,38  Physicians did not emphasize too 
much on social stigma associated with Insulin coherent 
to findings of DAWN study.35The contribution of 
physicians in delay of initiation of insulin was also 
admitted by physicians, majority of whom belonged to 
private sector, as had been observed in few previous 
studies too, but it was more common in general 
practitioners and nurses.27,31,32, 35,39,40 
The recommendations regarding cease or prevention 
of delay presented by health care providers basically 
comprised of awareness of patients, recruitment of 
diabetic nurses, diabetic educators and strict policies 
against quakes misdirecting patients whereas 
suggested actions by patients were ambitious like 
domiciliary services and insulin tablets. The 
recommendations to prevent delay presented by our 
participants were distinctive from interventions in 
practice internationally except awareness and training 
of patients that is considered the best intervention and 
was valued by our participants too. 23,24,41-46 All the 
patients had not initiated Insulin yet but still we did 
not comply with the term refusal and referred to delay 
because there still is optimism that they initiate it in 
future.  
Conclusion 
The  imperative factors identified by patients and 
physicians responsible for delay of initiation of insulin 
in type 2 diabetic patients included fears of injection, 
pain and its side effects, difficult and lifelong 
application, cost, storage issues, last resort of 
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treatment, misdirection from quacks and patients 
reluctance tempting doctors to holdup Insulin till 
inevitable.  
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